1207449-52-2

Upstream product

• 6601-22-5 2,6-Dichloro-4-morpholino-1,3,5-triazine 
• 10272-07-8 3.5-dimethoxyaniline 

Downstream Products

• 1207449-55-5 N-[2-(7-chloro-quinolin-4-ylamino)-ethyl]-N'-(3,5-dimethoxy-phenyl)-6-morpholin-4-yl-[1,3,5]triazine-2,4-diamine 
• 1207449-57-7 C₂₇H₃₁ClN₈O₃ 
• 1207449-59-9 C₃₀H₃₇ClN₈O₃ 
• 1207449-58-8 C₂₈H₃₃ClN₈O₃ 
• 1207449-60-2 C₃₂H₄₁ClN₈O₃ 
• 1393922-30-9 N-(2-aminoethyl)-N'-(3,5-dimethoxyphenyl)-6-(morpholin-4-yl)-1,3,5-triazine-2,4-diamine 

Relevant academic research and scientific papers

Synthesis and antimalarial-activity evaluation of tetraoxane-triazine hybrids and spiro[piperidine-4,3′-tetraoxanes]

A series of tetraoxane-triazine hybrids and spiro[piperidine-4,3′- tetraoxanes] have been synthesized, and all the compounds were screened for in vitro antimalarial activity against chloroquine-sensitive (D6) and chloroquine-resistant (W2) strains of Plas

Synthesis, antimalarial activity and cytotoxicity of 4-aminoquinoline-triazine conjugates

A series of 4-aminoquinoline-triazine conjugates with different substitution pattern have been synthesized and evaluated for their in vitro antimalarial activity against chloroquine-sensitive and resistant strains of Plasmodium falciparum. Compounds 16, 19, 28 and 35 exhibited promising antimalarial activity against both strains of P. falciparum. Cytotoxicity of these compounds was tested against three cell lines. Several compounds did not show any cytotoxicity up to a high concentration (48 μM), others exhibited mild toxicities but selective index for antimalarial activity was high for most of these conjugates.